Overview

Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis

Status:
Unknown status

Trial end date:
2018-07-01

Target enrollment:

Participant gender:

Summary

The proposed 3-month study is a prospective, open-label, multicentre, phase IV, proof of concept study. The study is designed to assess the effect on the quality of vision of IKERVIS® (1mg/mL ciclosporin) eye drops administered once daily in dry eye disease (DED) patients with severe keratitis, as well as its safety and efficacy.

Phase:

Phase 4

Details

Lead Sponsor:

Santen SAS

Treatments:

Cyclosporine
Cyclosporins
Ophthalmic Solutions
Tetrahydrozoline